{{Rsnum
|rsid=6555545
|Gene=LOC729506
|Chromosome=5
|position=8440615
|Orientation=plus
|GMAF=0.2902
|Gene_s=SNORD19B
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 9.7 | 42.5 | 47.8
| HCB | 0.0 | 12.4 | 87.6
| JPT | 0.0 | 8.0 | 92.0
| YRI | 40.8 | 46.3 | 12.9
| ASW | 26.3 | 56.1 | 17.5
| CHB | 0.0 | 12.4 | 87.6
| CHD | 0.9 | 7.3 | 91.7
| GIH | 13.9 | 45.5 | 40.6
| LWK | 31.2 | 54.1 | 14.7
| MEX | 3.4 | 41.4 | 55.2
| MKK | 25.6 | 50.0 | 24.4
| TSI | 12.7 | 31.4 | 55.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs6555545
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 176. Study population/ethnicity: 87 European descent Caucasians and 89 Yorubans. Significance metric(s): p = 0.00003. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109439
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs6555545
|overall_frequency_n=38
|overall_frequency_d=124
|overall_frequency=0.306452
|n_genomes=27
|n_genomes_annotated=0
|n_haplomes=34
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}